EmotiZen is a research-based lab that has developed a new mobile and web app aiming to transform mental health care using its innovative bio-inspired AI models.
Mobile Mental Health Screening in EmotiZen via the Novel Brain-Inspired MCoG-LDPSNet
Our study introduces MCoG-LDPSNet, a novel brain-inspired predictive mental health algorithm that achieves world-class performance. The proposed MCoG-LDPSNet outperforms both traditional and state-of-the-art machine learning and deep learning approaches, delivering significantly higher accuracy in the early prediction of anxiety and depression. Integrated into the EmotiZen App, MCoG-LDPSNet enables early and scalable screening to promote individual mental well-being.
https://t.co/zAjWVScCL0
#ArtificialIntelligence #MentalHealthMonday #DeepLearning #MentalHealthSupport #machinelearing #MentalWellness #NeuralNetworks #BrainHealth #Innovation #Technology #MentalHealthCrisis #MentalStrength #DataScience #brainmapping #MCoGLDPSNet
Markets are under pressure, but opportunities can still emerge when company fundamentals show resilience.
$KURA is a name worth watching. Kura Oncology reported $22.84 million in Q3 revenue, with KOMZIFTI net product revenue increasing 53% sequentially to $13.9 million.
Management is also presenting at investor conferences this week, keeping the company's commercial progress in focus.
Our takeaway: KOMZIFTI's sequential revenue growth signals increasing commercial traction. The key question now is whether Kura can sustain that momentum and translate it into continued revenue growth. For investors, execution over the coming quarters will matter more than short-term market sentiment.
The story is developing. Stay tuned! 📉
#TradingSignals #Stocks #StockMarket #AlgoTrading #financialeducation #AI
Markets function in complex and sometimes manipulated ways. No trading strategy wins consistently in all conditions. Algorithmic trading is changing the game, and AI models such as our brain-inspired McoRNNMCD-ANN (https://t.co/Pu9lutsICc) can improve pattern recognition and execution when supported by rigorous validation, risk controls, and an awareness of market-structure risks (https://t.co/7nIyJ6Z1Z5).
We changed the way markets can be understood.
From Neurofinance to Neuroscience, our work on MCoRNNMCD-ANN, led by Prof. Dr. Christos Bormpotsis, has helped redefine how market behaviour can be modelled and anticipated.
Even in the post-ChatGPT era, our brain-inspired deep learning approach stands out as a major advance in business intelligence, combining neuroscience, behavioural finance, modular AI, and market forecasting.
Markets are not just numbers.
They are human decisions, emotions, biases, and neural patterns.
The next edge belongs to those who understand the mind behind the move.
[1] https://t.co/nXe88I0whe
[2] https://t.co/JQYCG4EwPl
[3] https://t.co/DA723cINKj
#Neurofinance #Neuroscience #AI #DeepLearning #QuantFinance #Trading #FinTech #businessintelligence
Fear is loud in the markets right now, but fear is not a trading strategy.
Not every stock falls forever. Not every business breaks in a downturn.
Hard times separate speculation from strength. They also create rare chances to own great companies at better prices.
Stay calm. Stay selective.
This is what happens when someone confuses a compelling AI story with an actual trading process; oversized bets, no margin for being early, and a portfolio that needs the future to arrive on schedule.
Big claims about AGI are not evidence, and neither are insider vibes, connections, or conviction.
You can be right about the destination and still get destroyed because you treated a speculative timeline as a trading edge.
You could buy 100 shares of $CRDO right now for about $19,050.
Or you could sell the $160 put expiring November 20 and get paid roughly $635 to wait.
Credo posted revenue of $479M last quarter, up 115% year over year, and guided this quarter to $525M to $535M. The stock still fell about 20% the day after that report, and AI hardware names have sold off again over the last two sessions. That pullback is the setup.
Selloffs spike implied volatility, and that's when you want to be selling premium, not buying it. The $160 put is trading at about 79% IV right now.
Credo's next earnings are expected around the start of December, after this put expires, so this trade doesn't have to sit through a report.
The plan is to close at 50% of max profit, buying the put back around $3.18. Half the credit for a fraction of the time in the trade.
If $CRDO drops toward $160 and the thesis still holds, you could roll down and out for another credit. If you get assigned, your cost basis is $153.65, about 19% below today's price, and you can start selling covered calls against the shares.
$160 strike. ~16% cushion. ~0.20 delta. 38 DTE. ~4.0% return on capital, ~38% annualized.
Only sell this if $153.65 is a price you'd genuinely want to own $CRDO at. Not financial advice.
Some brokerage platforms are locking stock prices to increments of €0.05 per share, so we’re not allowed to buy at prices like €0.01 or even €4.01. For example, if a stock is trading at €4.00, the system only allows us to place buy orders at €4.05, not at any price in between. The same restriction applies when selling: we can only sell in €0.05 steps.
This is seriously hurting our trades. Being forced to trade only in 5‑cent increments can wipe out small but valid opportunities and feels unfair, even potentially illegal. We’re trying to capture specific prices, but some brokers keep rounding everything to the 5 cents. It’s a shame, really frustrating.
The advice to “don’t buy stocks, buy the companies behind them” is often repeated as investment wisdom. But taken too literally, it can be misleading. $NKE is a good example. Be careful whose advice you follow, and always think critically before investing.
Did you follow our probability models this week?
$ACIU 🟢 (+9.85%)
$ONDS 🟢 (+3.94%)
$PLTR 🟢 (+3.44%)
$KURA 🟢 (+1.54%)
Zero discretionary mandates. No narrative-driven allocation.
Our MCoRNNMCD-ANN framework ranks asymmetric risk-reward profiles using a proprietary, high-dimensional neural network architecture 👉 https://t.co/nXe88I0whe
The result? Systematic exposure to high-conviction alpha opportunities driven by rigorously validated algorithms.
$ACIU is rallying! Not strategy; algorithms and novel brain-inspired computational methods developed by Dr. Christos Bormpotsis are changing the financial game! https://t.co/bnR4YtkFCW
Did you follow our top pick $KURA recommendation from yesterday, or are you still drowning in bloodbaths? This is what happens when real validated algorithms outperform state-of-the-art methods. The paper that changed the game 👇
https://t.co/bnR4YtkFCW
The paper that changed algorithmic trading!
No hype. No fake claims. Just rigorously validated outperformance.
Meet MCoRNNMCD-ANN, the novel brain-inspired neural network that is officially rewriting the rules of Forex prediction.
Here is exactly why this paper is a massive paradigm shift for quants: 👇
🧠 Neuroscience Meets Quant: It mathematically simulates the human brain's risk-processing centers (the vmPFC & AIC) to navigate unpredictable market chaos.
📊 Multi-Modal Mastery: It doesn't just look at charts. It processes raw price action and market sentiment simultaneously.
The result? Tremendous predictive accuracy that systematically crushes traditional monolithic CNNs and RNNs. It captures market uncertainty effectively and kills the overfitting that ruins standard trading bots.
The era of fragile trading models is dead.
Read the peer-reviewed breakthrough here: https://t.co/Pu9lutsICc
Neurofinance: AI Meets Decision Science
Lucid Financials highlights neurofinance in a way that aligns with our MCoRNNMCD-ANN, which we designed and deployed for real-world neurofinance predictions [1]. MCoRNNMCD-ANN was among the first to underscore the future of brain-inspired AI for financial decision-making, and its value is even clearer in the post-ChatGPT era, where it outperformed state-of-the-art methods [2,3,4]. This is why validated, award-winning algorithms matter in algorithmic trading.
[1] https://t.co/J6AfetC0mS
[2] https://t.co/nXe88I0whe
[3] https://t.co/7nIyJ6Z1Z5
[4] https://t.co/YLljoF62Ox